S H Arshad1, W Karmaus, R Kurukulaaratchy, A Sadeghnejad, M Huebner, S Ewart. 1. The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport, Isle of Wight and IIR Research Division, University of Southampton, Southampton, UK. sha@soton.ac.uk
Abstract
BACKGROUND: Atopic eczema is characterized by Th2-dominant immunity with the cytokine interleukin 13 and the transcription factor GATA binding protein 3 playing a critical role. OBJECTIVES: We assessed the association of polymorphisms in the IL13 and GATA3 genes with childhood eczema. METHODS: A birth cohort (n = 1456) was established on the Isle of Wight in 1989 and followed at the ages of 1 (n = 1167), 2 (n = 1174), 4 (n = 1218) and 10 years (n = 1373) to determine the prevalence of allergic disease including eczema. At 4 and 10 years, skin prick testing was performed. Whole blood samples (n = 923) were obtained at the 10-year assessment, stored frozen, and genotyped. Five polymorphisms from IL13 and seven from GATA3 were genotyped for this analysis. Repeated measurement analyses were conducted for the occurrence of eczema at ages 1, 2, 4 and 10 years. All analyses were adjusted for maternal and paternal eczema, low birth weight (< 2500 g), breastfeeding >or= 3 months and age. RESULTS: IL13 was not associated with childhood eczema. For GATA3, the single nucleotide polymorphism (SNP) rs2275806 (promoter region) showed an increased odds ratio for atopic eczema independent of whether the comparison group had a positive skin prick test. The SNP rs444762 (intron 3 region) was associated with atopic eczema in comparison with children without eczema. The increased relative risks remained significant after adjustment for multiple testing only for rs2275806 (P < 0.05). CONCLUSIONS: A SNP in GATA3 is associated with atopic eczema. This finding highlights the importance of GATA3 as an immune-modulating gene in atopic eczema.
BACKGROUND:Atopic eczema is characterized by Th2-dominant immunity with the cytokine interleukin 13 and the transcription factor GATA binding protein 3 playing a critical role. OBJECTIVES: We assessed the association of polymorphisms in the IL13 and GATA3 genes with childhood eczema. METHODS: A birth cohort (n = 1456) was established on the Isle of Wight in 1989 and followed at the ages of 1 (n = 1167), 2 (n = 1174), 4 (n = 1218) and 10 years (n = 1373) to determine the prevalence of allergic disease including eczema. At 4 and 10 years, skin prick testing was performed. Whole blood samples (n = 923) were obtained at the 10-year assessment, stored frozen, and genotyped. Five polymorphisms from IL13 and seven from GATA3 were genotyped for this analysis. Repeated measurement analyses were conducted for the occurrence of eczema at ages 1, 2, 4 and 10 years. All analyses were adjusted for maternal and paternal eczema, low birth weight (< 2500 g), breastfeeding >or= 3 months and age. RESULTS:IL13 was not associated with childhood eczema. For GATA3, the single nucleotide polymorphism (SNP) rs2275806 (promoter region) showed an increased odds ratio for atopic eczema independent of whether the comparison group had a positive skin prick test. The SNP rs444762 (intron 3 region) was associated with atopic eczema in comparison with children without eczema. The increased relative risks remained significant after adjustment for multiple testing only for rs2275806 (P < 0.05). CONCLUSIONS: A SNP in GATA3 is associated with atopic eczema. This finding highlights the importance of GATA3 as an immune-modulating gene in atopic eczema.
Authors: P E Graves; M Kabesch; M Halonen; C J Holberg; M Baldini; C Fritzsch; S K Weiland; R P Erickson; E von Mutius; F D Martinez Journal: J Allergy Clin Immunol Date: 2000-03 Impact factor: 10.793
Authors: T C van der Pouw Kraan; A van Veen; L C Boeije; S A van Tuyl; E R de Groot; S O Stapel; A Bakker; C L Verweij; L A Aarden; J S van der Zee Journal: Genes Immun Date: 1999-09 Impact factor: 2.676
Authors: H Hakonarson; U S Bjornsdottir; E Ostermann; T Arnason; A E Adalsteinsdottir; E Halapi; D Shkolny; K Kristjansson; S A Gudnadottir; M L Frigge; D Gislason; T Gislason; A Kong; J Gulcher; K Stefansson Journal: Am J Respir Crit Care Med Date: 2001-12-01 Impact factor: 21.405
Authors: K Beyer; R Nickel; L Freidhoff; B Björkstén; S K Huang; K C Barnes; S MacDonald; J Forster; F Zepp; V Wahn; T H Beaty; D G Marsh; U Wahn Journal: J Invest Dermatol Date: 2000-11 Impact factor: 8.551
Authors: T D Howard; P A Whittaker; A L Zaiman; G H Koppelman; J Xu; M T Hanley; D A Meyers; D S Postma; E R Bleecker Journal: Am J Respir Cell Mol Biol Date: 2001-09 Impact factor: 6.914
Authors: Cristina de Guzman Strong; Philip W Wertz; Chenwei Wang; Fan Yang; Paul S Meltzer; Thomas Andl; Sarah E Millar; I-Cheng Ho; Sung-Yun Pai; Julia A Segre Journal: J Cell Biol Date: 2006-11-20 Impact factor: 10.539
Authors: Ali H Ziyab; Wilfried Karmaus; Hongmei Zhang; John W Holloway; Susan E Steck; Susan Ewart; Syed Hasan Arshad Journal: Int Arch Allergy Immunol Date: 2014-09-23 Impact factor: 2.749
Authors: S Hasan Arshad; John W Holloway; Wilfried Karmaus; Hongmei Zhang; Susan Ewart; Linda Mansfield; Sharon Matthews; Claire Hodgekiss; Graham Roberts; Ramesh Kurukulaaratchy Journal: Int J Epidemiol Date: 2018-08-01 Impact factor: 7.196
Authors: G A Lockett; N Soto-Ramírez; M A Ray; T M Everson; C-J Xu; V K Patil; W Terry; A Kaushal; F I Rezwan; S L Ewart; U Gehring; D S Postma; G H Koppelman; S H Arshad; H Zhang; W Karmaus; J W Holloway Journal: Allergy Date: 2016-03-29 Impact factor: 13.146
Authors: Kelly Speiran; Daniel P Bailey; Josephine Fernando; Matthew Macey; Brian Barnstein; Motunrayo Kolawole; Dana Curley; Stephanie S Watowich; Peter J Murray; Carole Oskeritzian; John J Ryan Journal: J Leukoc Biol Date: 2009-02-19 Impact factor: 4.962